Get started
Author

Torben Kasparek

Observed names: T. Kasparek, T., Kasparek
OpenAlex ID: A5000701495
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
2023 · April W. Armstrong, Barbra Bohannan, et al. · Dermatology · 56
PDF
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real‐world experience from EU5 and US
2022 · J.R. Ingram, V. Bettoli, et al. · Journal of the European Academy of Dermatology and Venereology · 51
PDF
Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey
2022 · April Armstrong, Barbra Bohannan, et al. · Dermatology and Therapy · 47
PDF
Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study
2019 · D. Thaçi, A. Körber, et al. · Journal of the European Academy of Dermatology and Venereology · 31
PDF
Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study
2017 · A. Körber, D. Thaçi, et al. · Journal of the European Academy of Dermatology and Venereology · 17
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System ( IHS4 ): A post hoc analysis of the SUNSHINE and SUNRISE trials
2024 · Christos C. Zouboulis, Athanassios Kyrgidis, et al. · Journal of the European Academy of Dermatology and Venereology · 16
PDF
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab
2023 · Christos C. Zouboulis, Errol P. Prens, et al. · Journal of the European Academy of Dermatology and Venereology · 14
Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research
2023 · Joslyn S Kirby, Antonio Martorell, et al. · British Journal of Dermatology · 11
Secukinumab versus guselkumab in the complete resolution of ustekinumab‐resistant psoriatic plaques: The ARROW study
2023 · James Krueger, Richard G. Langley, et al. · Experimental Dermatology · 8
PDF
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
2021 · Curdin Conrad, Christine-Elke Ortmann, et al. · Dermatology and Therapy · 7
PDF
Treatment Satisfaction in Patients with Hidradenitis Suppurativa: A Real-World Survey from the EU5 and USA
2024 · John R. Ingram, Vincenzo Bettoli, et al. · Dermatology · 6
42981 Secukinumab and concomitant antibiotic use in patients with moderate-to-severe hidradenitis suppurativa: Week 16 efficacy and safety results from the Phase 3 SUNSHINE and SUNRISE trials
2023 · Georgios Kokolakis, Antonio Martorell, et al. · Journal of the American Academy of Dermatology · 4
PDF
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region
2022 · Miguel Alpalhão, Joana Duarte, et al. · BioDrugs · 4
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis
2022 · Kristian Reich, Xenophon Baraliakos, et al. · British Journal of Dermatology · 4
42927 Unmet needs in treatment options and management strategies in hidradenitis suppurativa: understanding the patient perspective through social media listening
2023 · Christopher Sayed, Antonio Martorell, et al. · Journal of the American Academy of Dermatology · 1
PDF
42652 Efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa previously treated with biologic therapy: Week 16 results from the SUNSHINE and SUNRISE trials
2023 · Christos C. Zouboulis, Thierry Passeron, et al. · Journal of the American Academy of Dermatology · 1
16317 Characterization of patient clusters based on response to treatment with secukinumab: A “pattern recognition” analysis of pooled phase 3 data
2020 · Kristian Reich, Esteban Daudén, et al. · Journal of the American Academy of Dermatology · 1
Supplementary Material for: Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
2023 · A.W., Armstrong, B., Bohannan, et al. · Figshare
Supplementary Material for: Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
2023 · A.W., Armstrong, B., Bohannan, et al. · Figshare
Supplementary Material for: Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
2023 · A.W., Armstrong, B., Bohannan, et al. · Figshare
25385 Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analyses from phase III studies in psoriasis and psoriatic arthritis (PsA)
2021 · Kristian Reich, Xenofon Baraliakos, et al. · Journal of the American Academy of Dermatology
27476 Increased benefit of secukinumab vs ustekinumab in patients with psoriasis regardless of previous systemic psoriasis therapy: Pooled analysis of the phase 3 CLEAR and CLARITY trials
2021 · Andrew Blauvelt, Stephen Tyring, et al. · Journal of the American Academy of Dermatology
Secukinumab-Behandlung der mittelschweren bis schweren Plaque-Psoriasis in der klinischen Routineversorgung: Baselinecharakteristika, Vortherapien und Transitionszeiten der ersten 2000 Psoriasispatienten in der PROSPECT Studie
2018 · Torben Kasparek, Andreas Körber
Secukinumab Shows Significant Efficacy in Difficult to Treat Palmoplantar Psoriasis: 1.5-Year-Data From the GESTURE Study
2017 · Alice B. Gottlieb, John Sullivan, et al. · Touro Scholar (Touro College)
Works count: 25
Citation count: 279
H-index: 8
I10-index: 8
Year
Topic
Type